Morningstar
•
Sep 03, 2026
Qiagen N.V.: Innovation and Execution to Drive Above-Market Growth for Qiagen
Summary
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Repligen Corporation
Sep 03, 2026
•
RGEN
Analyst Report: Alnylam Pharmaceuticals, Inc.
Sep 02, 2026
•
ALNY
NBIX: Raising target price to $172.00
Sep 02, 2026
•
NBIX
BMRN: Lowering target price to $71.00
Sep 02, 2026
•
BMRN
QDEL: Lowering target price to $11.00
Sep 02, 2026
•
QDEL
